Zevra Therapeutics (NASDAQ:ZVRA) Receives Buy Rating from BTIG Research

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $27.00 target price on the stock, up from their previous target price of $23.00. BTIG Research’s target price suggests a potential upside of 101.64% from the company’s previous close.

A number of other equities analysts have also issued reports on ZVRA. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday. Wall Street Zen lowered shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Canaccord Genuity Group raised their price objective on shares of Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Zevra Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Zevra Therapeutics Price Performance

Shares of ZVRA stock traded up $1.30 during mid-day trading on Tuesday, hitting $13.39. 3,385,059 shares of the stock traded hands, compared to its average volume of 1,262,932. The stock has a market cap of $791.62 million, a P/E ratio of 6.68 and a beta of 0.91. The stock’s fifty day moving average is $10.37 and its two-hundred day moving average is $9.39. Zevra Therapeutics has a 52-week low of $7.16 and a 52-week high of $13.80.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.06 by $0.12. The firm had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. As a group, equities analysts forecast that Zevra Therapeutics will post 0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth about $53,000. Russell Investments Group Ltd. lifted its position in shares of Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning acquired a new stake in shares of Zevra Therapeutics during the second quarter worth about $92,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Zevra Therapeutics during the second quarter worth approximately $99,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.